AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02902653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral misoprostol
Description: hourly titrated misoprostol
Study NCT02902653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal misoprostol
Description: Administration of 25 microgs every 6 hours, maximum 150 microgr
Study NCT02902653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal dinoprostone
Description: Vaginal delivery system of 10mg of dinoprostone
Study NCT02217488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DG3173
Study NCT02217488 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02147067 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02619305 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social network tie
Description: Participants will be social network ties of women receiving a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises.
Study NCT00427778 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: incontinence ring
Description: Incontinence ring fitted to patient's anatomy (by choosing appropriate size). It is worn continually for the duration of the treatment period.~Intravaginal incontinence ring placed proximally in the posterior vaginal fornix. Knob located at mid-urethra.
Study NCT01101997 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Zeltiq System
Description: Noninvasive cooling is applied to the treatment area with a defined cooling rate and duration.
Study NCT04604470 — intervention group
Intervention type: OTHER
Intervention: Decision tool
Description: no intervention.
Study NCT03110263 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent internet-based self-help
Description: Internet-based self-help on the basis of (Perlis, M. L., Jungquist, C., Smith, M. T., \& Posner, D., 2006). The self-help program consists of eight text-based sessions and tasks. All participants in the active conditions receive guidance during 8-weeks treatment.
Study NCT03110263 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-based sleep restriction
Description: Internet-based self-help on the basis of (Perlis, M. L., Jungquist, C., Smith, M. T., \& Posner, D., 2006). The self-help program consists of five text-based sessions and tasks. All participants in the active conditions receive guidance during 8-weeks treatment.
Study NCT01316887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 125/25 mcg once-daily GSK573719/GW642444
Description: GSK573719/GW642444
Study NCT01316887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 125mcg once-daily GSK573719
Description: GSK573719
Study NCT01316887 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo once-daily
Description: inactive
Study NCT03336697 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Nasal swab
Description: a nasal swab will be performed by a trained physician by gently passing of a cotton swab in the nasal passage to get samples from middle meatus. This will be performed under guide of nasal anterior endoscopy to visualize the location of sampling. The cotton swab heads will be placed in sterile tubes and frozen at -80°C until DNA extraction.
Study NCT00107978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telavancin
Description: Telavancin 10 mg/kg/day, IV for up to 14 days.
Study NCT00107978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Vancomycin 1 Gm IV administered every 12 hrs for up to 14 days.
Study NCT01391429 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Decision Support Tool
Description: Six minute digital video illustrating specific treatments for three different levels of medical care: life-prolonging care, basic care and comfort oriented care.
Study NCT02099136 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UV Light Therapy
Description: Undergo UV-irradiation
Study NCT02099136 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given PO
Study NCT02099136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Given PO
Study NCT02099136 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo skin biopsy
Study NCT02099136 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaging Biomarker Analysis
Description: Correlative studies
Study NCT04696133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fine motor skills
Description: stretching and strengthening exercises in addition to exercises to enhance fine motor skills
Study NCT04696133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sensory integration
Description: * Tactile stimulation~* Proprioceptive stimulation
Study NCT00739609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1-methyl-D-tryptophan
Description: D-1MT will be administered in escalating doses. Initial dosing will be 200 mg by mouth daily with escalation planned to 2000 mg by mouth daily and potentially higher doses in subsequent cohorts if tolerated and pharmacokinetic and biologic data support further dose escalation.
Study NCT01980602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supervised Exercise program
Study NCT01637285 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04856883
Description: Dose A
Study NCT01637285 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04856883
Description: Dose B
Study NCT01637285 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04856883
Description: Dose C
Study NCT01637285 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04856883
Description: Dose D
Study NCT02647788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen/Ibuprofen
Description: After hand surgery, take Acetaminophen 650 mg/Ibuprofen 400 mg every 6 hours as needed for pain until postoperative clinic visit
Study NCT02647788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen/Codeine
Description: After hand surgery, take Acetaminophen 300mg/Codeine 30 mg every 6 hours as needed for pain until postoperative clinic visit
Study NCT01053338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen and Diphenhydramine Citrate
Description: Ibuprofen and Diphenhydramine Citrate 200mg/38mg Caplets
Study NCT01053338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen and Diphenhydramine Citrate
Description: Ibuprofen and Diphenhydramine Citrate 200mg/38mg Caplets
Study NCT04656366 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary Angiography
Description: Diagnostic Coronary angiography for patients that presented angina after a previous CABG operation; eventually interventional procedure with PCI (Percutaneous Coronary Intervention)
Study NCT05514743 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 6 minute walk test , Blood pressure monitoring
Description: Heart rate monitors can assess a person's heart rate and reveal whether it is high or low. Heart rate Trusted Source is a clinical indicator of overall cardiac health, and it can also help a person determine their performance during a workout.~Six minute walk test:~It will be carried out before and after interventions to determine the patients functional capacity (in the 7th.day \&in the 21st.day.) It will be used as a training tool as well as an assessment tool. They will receive conventional physical therapy program which includes deep breathing exercise in form of (diaphragmatic, apical and costal breathing), Training about right way of cough and early ambulation from bed for 3 sessions / week, twice daily for 21 days.
Study NCT03942926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Patients will receive sirolimus for 6 months.
Study NCT02334098 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 supplemented drink
Description: The drink has apple/ pear/ pomegranate taste which is well accepted by children and adolescents, is rich in natural antioxidants to help prevent oxidation of omega-3. The drink can be taken at any time during the day.~1/3 of the participants will be assigned to the omega-3 group after randomization. They are going to take the treatment for 6 months. They will be assessed at baseline, end of treatment and 6 months post-treatment.
Study NCT04198948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole (20 mg) will be administered orally once daily for 5 days in one of the two treatment periods.
Study NCT04198948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: Placebo will be administered orally once daily for 5 days in one of the two treatment periods.
Study NCT04198948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gliclazide
Description: Gliclazide (40 mg) will be administered orally once, concomitantly with omeprazole or placebo on day 5.
Study NCT06224010 — intervention group
Intervention type: OTHER
Intervention: Respiratory drive and effort assessment
Description: The use of a neurally-adjusted ventilatory assist catheter, the measurement of electrical activity of the diaphragm, ∆Pocc, P0.1, and other ventilatory parameters to assess respiratory drive and effort in three cohorts of patients
Study NCT03520062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml
Description: Treatment with Liraglutide (3.0mg per day) for \~6 weeks
Study NCT02334098 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Smartfish
Description: Treatment duration is 6 months. They will be assessed at baseline (0 months), end of treatment (6 months) and 6 months post-treatment (12 months).
Study NCT04015752 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: culture from infected site
Description: ESR ,CRP,CBC, Renal and Liver function will be done on admission and follow up Culture: On admission Urine and blood as well as sputum culture acc. To the cause of infection. Culture from suspected site of infection in catheter related infections.
Study NCT03718169 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: Female smokers will be asked to complete a structured questionnaire at smoking hotspots. In addition, the smokers will respond to the same questionnaire at 6 months via telephone. The structured questionnaire will collect information related to their demographic characteristics and quitting behaviors, i.e. self-reported abstinence, smoking reduction and quit attempts.
Study NCT04246502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine and Pyrotinib
Description: Pyrotinib 400mg orally daily until progressive disease
Study NCT04246502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine,Trastuzumab, and Pertuzumab
Description: as instruction
Study NCT04787861 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: motorized movement therapy
Description: The study group received an aerobic exercise regimen using a motorized movement therapy device 3 times /week in addition to the same traditional program used with the control group.
Study NCT04787861 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motorized movement therapy
Description: The study group received an aerobic exercise regimen using a motorized movement therapy device 3 times /week in addition to the same traditional program used with the control group.
Study NCT00755950 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Silymarin
Description: 280 mg three times daily for four weeks
Study NCT00755950 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Silymarin
Description: 420 mg three times daily for four weeks
Study NCT00755950 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lactose monohydrate
Description: Lactose monohydrate 326.95 mg three times daily for four weeks
Study NCT01897571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Patients who received 800 mg of tazemetostat, BID, administered in continuous 28-day cycles.
Study NCT01897571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Patients who received 40 mg/m\^2 prednisolone once daily on Days 1-5 and 15-19 of Cycles 1-4.
Study NCT01897571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Patients who received 100 mg to 1600 mg of tazemetostat, BID, administered in continuous 28-day cycles.
Study NCT00359177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW679769
Description: GW679769 will be available in dose strength of 50 mg tablets. Subjects will receive two tablets of 50 mg orally once daily in the morning
Study NCT02886884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 million Allogeneic Mesenchymal Human Stem Cells
Description: 1 single intravenous infusion
Study NCT02886884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 million Allogeneic Mesenchymal Human Stem Cells
Description: 1 single intravenous infusion
Study NCT02030496 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open reduction and internal fixation
Description: The surgery will be performed by a certified trauma surgeon. After the fracture site is exposed, the fracture will be reduced and provisionally fixed with K-Wires and reduction forceps. An appropriate volar locking plate which best suits the anatomy of the wrist and the fracture type will be selected. Screw placement and fracture reduction will be confirmed intra-operatively by radiographic images. No post-operative fixation will be applied and patients will be instructed to use the affected extremity in daily activities as pain allows. According to Dutch treatment standards, vitamin C 500 milligrams will be prescribed to all patients at initial presentation and for a duration of two months in order to prevent Complex Regional Pain Syndrome.
Study NCT02030496 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Closed reduction and plaster
Description: Closed reduction will be performed according to the Robert-Jones method. This involves increasing the deformity first, then applying continuous traction and immobilising wrist and hand in the reduced position. Additional radiographs will be performed to verify the quality of the reduction. After this has been confirmed, the wrist will be immobilised according to Dutch guidelines: a splint for one week followed by a circular cast for another four weeks. According to Dutch treatment standards, vitamin C 500 milligrams will be prescribed to all patients at initial presentation and for a duration of two months in order to prevent Complex Regional Pain Syndrome.
Study NCT04532411 — intervention group
Intervention type: OTHER
Intervention: Personal Protective Testing Booth
Description: Health personnel who utilize the Hexapod will remain in the booth and utilize durable gloves attached to ports through a plexiglass wall in order to administer a nasal swab for SARS-CoV-2 (COVID-19) testing. Patient escorts and housekeeping/sanitation staff perform additional tasks outside of the booth such as escorting the patient to the correct testing bay and dropping off testing vials and printed information, collect samples and deposit in the appropriate location after testing is complete, and sanitizing the patient bay before a subsequent patient is tested there.
Study NCT00636961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 300μg
Description: 300μg indacaterol maleate inhalation powder in hard gelatin capsules administered via Concept1 inhalation device
Study NCT00636961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo devices and hard gelatin capsules
Study NCT05266859 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Calcium hydroxide
Description: Calcium hydroxide in the power/liquid form will be used and placed on the exposed pulp
Study NCT05266859 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MTA
Description: Mineral trioxide aggregate will be used as a powder / liquid form and placed over the exposed pulp
Study NCT05266859 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRF
Description: PRF will be placed directly over the exposed pulp
Study NCT01687842 — intervention group
Intervention type: OTHER
Intervention: Evaluation of 45,X Turner syndrome patients
Description: Evaluation of 45,X Turner syndrome patients
Study NCT02045732 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06342674 0.25 mg/kg
Description: Bi-Weekly Subcutaneous Injections X 6
Study NCT02045732 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Bi-Weekly Subcutaneous Injections X 6
Study NCT02045732 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06342674 1.5 mg/kg
Description: Bi-Weekly Subcutaneous Injections X 6
Study NCT02045732 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06342674 6.0 mg/kg
Description: Bi-Weekly Subcutaneous Injections X 6
Study NCT01870297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3025876
Description: Administered SQ
Study NCT01870297 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SQ
Study NCT01870297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Administered SQ
Study NCT01870297 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liraglutide
Description: Administered SQ
Study NCT00770666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch, nicotine inhaler, bupropion
Description: Patch - 21 mg - taper as able Inhaler - as needed Bupropion SR 150 mg daily
Study NCT00770666 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: 21 mg daily for 6 weeks followed by 14 mg for 2 weeks and then 7 mg for 2 weeks
Study NCT02477709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Gefapixant oral tablet (150 mg administered as three 50 mg tablets) - single dose only
Study NCT01635309 — intervention group
Intervention type: OTHER
Intervention: Coronary CT Angiogram
Description: pre-operative coronary CTA
Study NCT01488396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.05%cyclosporin eye drop
Description: use twice daily for 6 months
Study NCT02770846 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate loading
Study NCT02770846 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed loading
Study NCT04212975 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: joint lavage with dextrose
Description: joint lavage with dextrose
Study NCT02471482 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mozart music lullaby
Description: Recorded Mozart Lullaby will be played. The noise level will be kept below 45db as recommended by American Academy of Pediatrics and will be monitored by sound monitor placed in incubator during the study period. Enrolled babies will have hearing screening performed prior to discharge from hospital.
Study NCT05595811 — intervention group
Intervention type: OTHER
Intervention: outcome following surgery
Study NCT04485754 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine FU
Description: Participant will get telemedicine follow-up visit at 1, 3, and 6 months or 1 and 6 months after discharge from hospital.
Study NCT04485754 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Office FU
Description: Participant will get office follow-up visit at 1, 3, and 6 months or 1 and 6 months after discharge from hospital.
Study NCT02089412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2006
Study NCT01301703 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed)
Description: a single 0.5-mL intramuscular injection into the deltoid muscle of the upper arm
Study NCT03121209 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Revascularization
Description: Patients in this arm are randomized to CEA/CAS plus IMM
Study NCT03121209 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Medical Management (IMM) alone
Description: Patients in this arm are randomized to intensive medical management (IMM) alone
Study NCT03634306 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultravision System
Description: Laparoscopic surgery will be performed with the Ultravision Visual Field Clearing System. This system is indicated for the clearance of smoke and other particulate matter that is created during laparoscopic surgery. Ultravision Visual Clearing System removes surgical smoke by means of electrostatic precipitation.
Study NCT03634306 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Laparoscopic Hysterectomy
Description: Laparoscopic hysterectomy will be performed according to standard of care without the Ultravision Visual Field Clearing System
Study NCT00776659 — intervention group
Intervention type: OTHER
Intervention: Aromasin
Description: Non-Interventional study design.
Study NCT00037713 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BEC2 Vaccine
Description: 5 vaccinations of BEC2 (2.5 mg) + BCG given day 1 of weeks 0,2,4,6 \& 10.